- Home
- PK vs KYMR Comparison
PK vs KYMR Comparison
Compare PK & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PK
- KYMR
- Stock Information
- Founded
- PK 1946
- KYMR 2015
- Country
- PK United States
- KYMR United States
- Employees
- PK N/A
- KYMR N/A
- Industry
- PK Real Estate Investment Trusts
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- PK Real Estate
- KYMR Health Care
- Exchange
- PK Nasdaq
- KYMR Nasdaq
- Market Cap
- PK 2.1B
- KYMR 1.8B
- IPO Year
- PK N/A
- KYMR 2020
- Fundamental
- Price
- PK $10.71
- KYMR $45.24
- Analyst Decision
- PK Hold
- KYMR Strong Buy
- Analyst Count
- PK 11
- KYMR 16
- Target Price
- PK $12.85
- KYMR $58.94
- AVG Volume (30 Days)
- PK 4.1M
- KYMR 1.1M
- Earning Date
- PK 07-31-2025
- KYMR 08-06-2025
- Dividend Yield
- PK 13.11%
- KYMR N/A
- EPS Growth
- PK 45.67
- KYMR N/A
- EPS
- PK 0.61
- KYMR N/A
- Revenue
- PK $2,602,000,000.00
- KYMR $58,885,000.00
- Revenue This Year
- PK $2.49
- KYMR $43.38
- Revenue Next Year
- PK $3.25
- KYMR $10.97
- P/E Ratio
- PK $17.53
- KYMR N/A
- Revenue Growth
- PK N/A
- KYMR N/A
- 52 Week Low
- PK $8.27
- KYMR $19.45
- 52 Week High
- PK $16.23
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- PK 57.04
- KYMR 59.74
- Support Level
- PK $10.12
- KYMR $43.51
- Resistance Level
- PK $10.88
- KYMR $45.45
- Average True Range (ATR)
- PK 0.30
- KYMR 1.81
- MACD
- PK 0.05
- KYMR -0.82
- Stochastic Oscillator
- PK 83.33
- KYMR 36.42
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels with 22,711 rooms across 37 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.